[go: up one dir, main page]

MX2022013625A - Metodo para evaluar los efectos de una composicion que comprende microorganismos en la microbiota intestinal. - Google Patents

Metodo para evaluar los efectos de una composicion que comprende microorganismos en la microbiota intestinal.

Info

Publication number
MX2022013625A
MX2022013625A MX2022013625A MX2022013625A MX2022013625A MX 2022013625 A MX2022013625 A MX 2022013625A MX 2022013625 A MX2022013625 A MX 2022013625A MX 2022013625 A MX2022013625 A MX 2022013625A MX 2022013625 A MX2022013625 A MX 2022013625A
Authority
MX
Mexico
Prior art keywords
composition
microorganisms
evaluating
effects
intestinal microbiota
Prior art date
Application number
MX2022013625A
Other languages
English (en)
Inventor
Simone Domenico Guglielmetti
Ruggero Rossi
Walter Fiore
Andrea Biffi
Original Assignee
Sofar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sofar Spa filed Critical Sofar Spa
Publication of MX2022013625A publication Critical patent/MX2022013625A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/10—Enterobacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un método para determinar la actividad probiótica/paraprobiótica de una composición que comprende microorganismos, en particular bacterias, dicho método basándose en la evaluación, mediante análisis metagenómico, del cambio cualitativo y/o cuantitativo de la microbiota fecal como consecuencia de consumir la composición. Además, la presente invención se refiere a un kit para llevar a cabo dicho método.
MX2022013625A 2013-09-06 2016-03-02 Metodo para evaluar los efectos de una composicion que comprende microorganismos en la microbiota intestinal. MX2022013625A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001473A ITMI20131473A1 (it) 2013-09-06 2013-09-06 Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale

Publications (1)

Publication Number Publication Date
MX2022013625A true MX2022013625A (es) 2022-11-16

Family

ID=49354801

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016002766A MX2016002766A (es) 2013-09-06 2014-09-05 Metodo para evaluar los efectos de una composicion que comprende microorganismos en la microbiota intestinal.
MX2022013625A MX2022013625A (es) 2013-09-06 2016-03-02 Metodo para evaluar los efectos de una composicion que comprende microorganismos en la microbiota intestinal.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016002766A MX2016002766A (es) 2013-09-06 2014-09-05 Metodo para evaluar los efectos de una composicion que comprende microorganismos en la microbiota intestinal.

Country Status (13)

Country Link
US (1) US20160348155A1 (es)
EP (1) EP3047032A1 (es)
JP (1) JP6701078B2 (es)
CN (1) CN105518150A (es)
BR (1) BR112016005064A2 (es)
CA (1) CA2923390A1 (es)
EA (2) EA034795B1 (es)
HK (1) HK1223982A1 (es)
IL (1) IL244391B (es)
IT (1) ITMI20131473A1 (es)
MX (2) MX2016002766A (es)
SG (1) SG11201601664VA (es)
WO (1) WO2015033304A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
CA3003579C (en) 2015-10-29 2023-08-22 Kabushiki Kaisha Yakult Honsha Method for measuring equol-producing ability
MA45327A (fr) 2016-05-13 2019-03-20 Sofar Spa Utilisation de probiotiques pour améliorer l'absorption des protéines
MA45288A (fr) * 2016-06-08 2019-04-17 Sofar Spa Nouvelle utilisation médicale de probiotiques
CN106318890A (zh) * 2016-10-21 2017-01-11 山东省农业科学院畜牧兽医研究所 一株分离自spf鸡嗉囊的产植酸酶卷曲乳杆菌菌株及其应用
IT201600122724A1 (it) * 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
IT201700101704A1 (it) * 2017-09-12 2019-03-12 Sofar Spa Nuovo uso per trattamento delle infezioni da clostridium difficile
AU2019209821A1 (en) * 2018-01-17 2020-08-27 Consorcio Centro de Investigación Biomédica en Red, M.P. Targeted interventions directed at reducing the levels of circulating succinate in a subject, and kits and method for determining effectiveness of said interventions
CN112384227A (zh) 2018-02-09 2021-02-19 N·V·努特里奇亚 含有不可消化寡糖的发酵配方物
WO2019195342A1 (en) * 2018-04-02 2019-10-10 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
CN110029155A (zh) * 2019-05-27 2019-07-19 天益健康科学研究院（镇江）有限公司 一种基于荧光定量pcr组合式肠道细菌检测方法
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
CN112980712A (zh) * 2019-12-14 2021-06-18 山东大学 一种调节高原人群情绪及肠道菌群稳定的微生物组合物及其应用
CN116287163A (zh) * 2023-02-17 2023-06-23 浙江大学 一种评估肠道菌群对菊粉的动态响应方法
EP4575491A1 (en) 2023-12-22 2025-06-25 Vilnius University Method for detecting volatile organic compounds in faecal matter odour

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
AU2002951270A0 (en) * 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
WO2005001109A2 (en) * 2003-05-06 2005-01-06 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Methods and compositions to detect microbes in fecal samples
CA2557543A1 (en) * 2004-02-27 2005-09-09 Stichting Laboratorium Voor Infectieziekten Method for detecting a microorganism in a fecal specimen
WO2006050479A2 (en) * 2004-11-01 2006-05-11 George Mason University Compositions and methods for diagnosing colon disorders
FI20051319A7 (fi) * 2005-12-22 2007-06-23 Gut Guide Oy Menetelmä eläimen ja/tai ihmisen ravitsemuksen ja hyvinvoinnin ja eläinten tuottavuuden seuraamiseksi ja kehittämiseksi
CN1840206A (zh) * 2006-01-19 2006-10-04 上海交通大学 人源菌群仔猪模型的构建及仔猪肠道中菌群分子检测方法
JP4590573B2 (ja) * 2006-02-21 2010-12-01 国立大学法人富山大学 感染症起因菌の迅速同定方法
CN101240315A (zh) * 2008-02-21 2008-08-13 上海交通大学 检测药物防癌效果的非损伤性分子方法
JP2010161944A (ja) * 2009-01-13 2010-07-29 Syngen Biotech Co Ltd 新型カゼイ菌の亜種（ｓｇ９６）及びこれを含有する菌抑制組成物及びその用途

Also Published As

Publication number Publication date
BR112016005064A2 (pt) 2017-11-21
US20160348155A1 (en) 2016-12-01
EA034795B1 (ru) 2020-03-23
CA2923390A1 (en) 2015-03-12
HK1223982A1 (zh) 2017-08-11
MX2016002766A (es) 2016-08-03
JP2016528926A (ja) 2016-09-23
SG11201601664VA (en) 2016-04-28
ITMI20131473A1 (it) 2015-03-07
EP3047032A1 (en) 2016-07-27
JP6701078B2 (ja) 2020-05-27
EA201690465A1 (ru) 2016-08-31
EA202090097A1 (ru) 2020-04-07
CN105518150A (zh) 2016-04-20
WO2015033304A1 (en) 2015-03-12
IL244391A0 (en) 2016-04-21
IL244391B (en) 2021-02-28

Similar Documents

Publication Publication Date Title
MX2022013625A (es) Metodo para evaluar los efectos de una composicion que comprende microorganismos en la microbiota intestinal.
MX2021002826A (es) Nuevo formato biespecifico adecuado para uso en tamizado de alto rendimiento.
GB2511221A (en) Methods and compositions for classification of samples
PH12014501108A1 (en) Anti-il-36r antibodies
IN2015DN02634A (es)
WO2013008102A3 (en) Methods and compositions for evaluating and/or treating chronic immune diseases
HK1210831A1 (en) Compositions and methods for detecting protease activity in biological systems
GB201516569D0 (en) Methods, compositions, and kits for nucleic acid analysis
SG10201803877YA (en) Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment
MX2015012733A (es) Metodos y composiciones para evaluar el estado renal usando adn libre de celulas de la orina.
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
UA115321C2 (uk) Спосіб та комплект для аналізу ahasl генів у рослин
WO2015009734A3 (en) Assays for antimicrobial activity and applications thereof
ECSP13012673A (es) Métodos y composiciones para inmunoterapia para enfermedad neural
MX2014015088A (es) Anticuerpos anti-tofacitinib y usos de los mismos para monitorear farmacos.
MY173304A (en) Induction of immune tolerance using methotrexate
MX357457B (es) Metodo para evaluar la integridad de la pared celular bacteriana.
WO2012164525A3 (en) Aging biomarkers
MX2015010023A (es) Anticuerpos anti-cd83 y su uso.
BR112014001792A2 (pt) método para a identificação da espécie, sorotipo e linhagem de um micro-organismo, polinucleotídeo isolado e kit
EP3112862A4 (en) Method for urine sample analysis, reagent for urine sample analysis, and reagent kit for urine sample analysis
EP3112863A4 (en) Method for urine sample analysis, reagent for urine sample analysis, and reagent kit for urine sample analysis
GB201107557D0 (en) Method
EP4328245A3 (en) Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
MX2014003415A (es) Mediadores azo.